Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Fam Plann Reprod Health Care ; 29(2): 23-9, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12681033

RESUMEN

OBJECTIVE: To assess insertion-linked pain and the short-term user-acceptability and safety of the GyneFix as compared with T-framed intrauterine devices (IUDs). DESIGN: A randomised controlled trial in an outpatient clinic setting. METHOD: Women requesting an IUD for emergency contraception (EC) were allocated to either the short-term arm (GyneFix versus Nova-T200, or the long-term arm (GyneFix versus Gyne-T380S, and then randomised within each group. Visual analogue scores were used to assess the women's perception of the pain associated with insertion, which was patient-blinded. Follow-up was double-blinded, at 6 weeks, with bleeding and pain recorded over this time. RESULTS: A total of 175 women received an IUD in the long-term arm. The short-term arm was discontinued due to low recruitment (17 women at 20 months) and therefore the results relate to the long-term arm only. Outcome was known in 98% of subjects. The actual insertion procedure was scored as more painful for the GyneFix, both by the women (p = 0.013) and the doctors making their assessment of the women's pain (p = 0.04). The women with GyneFix described less pain in the subsequent 30 days after insertion (p = 0.005). Only 13% of women with GyneFix requested removal as compared with 20% with Gyne-T380S, with the difference being attributed to removal due to pain. The bleeding pattern was similar for those using GyneFix and Gyne-T380S. CONCLUSIONS: Our study suggests that although the actual fitting may be more painful, pain is less during the 6 weeks after insertion of GyneFix and fewer women discontinue its use because of pain, as compared with Gyne-T380S. The high overall continuation rate of all emergency IUDs at 6 weeks and low morbidity seen in this study favours more frequent IUD insertion where unprotected intercourse has occurred, given also its higher efficacy over oral hormonal EC.


Asunto(s)
Tratamiento de Urgencia/métodos , Dispositivos Intrauterinos de Cobre , Aceptación de la Atención de Salud , Adolescente , Adulto , Sistemas de Liberación de Medicamentos , Femenino , Humanos , Dispositivos Intrauterinos de Cobre/efectos adversos , Dispositivos Intrauterinos de Cobre/clasificación , Londres , Dolor/epidemiología , Dolor/etiología , Dimensión del Dolor , Embarazo , Medicina Estatal , Hemorragia Uterina/epidemiología , Hemorragia Uterina/etiología
2.
J Fam Plann Reprod Health Care ; 29(2): 29-31, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12681034

RESUMEN

OBJECTIVE: To assess the force required for, and pain of, removal of the GyneFix as compared with T-framed intrauterine devices (IUDs). DESIGN: A comparative trial following patient-blinded randomisation in an outpatient clinic setting. METHOD: Women requesting an IUD for emergency contraception were fitted with either a GyneFix or a Gyne-T380S. For those requesting removal of the IUD, visual analogue scores were used to assess their perception of the associated pain, and a Newton dynamometer was used to measure the force required to remove the device. RESULTS: Removal required significantly more force for GyneFix as compared with Gyne-T380S (p = 0.004), but there was no significant difference in pain perceived by women during removal. Interestingly, anticipated pain was worse than actual pain experienced. CONCLUSION: Although more force is needed to remove the GyneFix as compared with the Gyne-T380S, this does not translate into more pain.


Asunto(s)
Remoción de Dispositivos/efectos adversos , Dispositivos Intrauterinos de Cobre , Dimensión del Dolor , Dolor/etiología , Adolescente , Adulto , Tratamiento de Urgencia/métodos , Femenino , Humanos , Dispositivos Intrauterinos de Cobre/efectos adversos , Dispositivos Intrauterinos de Cobre/clasificación , Londres , Dolor/clasificación , Aceptación de la Atención de Salud , Embarazo , Medicina Estatal , Torque
3.
Best Pract Res Clin Obstet Gynaecol ; 16(2): 133-54, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12041958

RESUMEN

In the more than 40 years since the combined oral contraceptive pill was first marketed, much information has been obtained as to its risks. Considerably less publicity has been given to the balancing benefits that have also emerged. There has been an increasing realization that the risks are focused in those women with recognised risk factors, meaning that the remainder can use the product with increasing reassurance. The doses of both hormones have also been lowered considerably since the early years. Thus, it can be a rational decision by a fully informed woman to use this form of contraception.


Asunto(s)
Anticonceptivos Orales Combinados , Enfermedades Cardiovasculares/inducido químicamente , Anticonceptivos Orales Combinados/efectos adversos , Edema Corneal/inducido químicamente , Trastorno Depresivo/inducido químicamente , Diabetes Mellitus/inducido químicamente , Enfermedades del Sistema Digestivo/inducido químicamente , Interacciones Farmacológicas , Femenino , Humanos , Infecciones/etiología , Inflamación/etiología , Ictericia/inducido químicamente , Libido , Náusea/inducido químicamente , Neoplasias/inducido químicamente , Neoplasias/prevención & control , Factores de Riesgo , Enfermedades de la Piel/inducido químicamente , Aumento de Peso
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA